Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.
The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who ...
An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only ...
The externally validated Childhood ITP Recovery Score predicted transient versus persistent ITP. The score also predicted bleeding and response to intravenous immunoglobulins. Prediction scores can ...
This might sound surprising, but getting diagnosed with immune thrombocytopenia (also known as idiopathic thrombocytopenic purpura, or ITP) can come as a relief. You can figure out ITP treatment, of ...
Researchers have used various definitions to estimate the incidence and prevalence of immune thrombocytopenia (ITP) yet haven’t corroborated available data with large, population-based, multinational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback